(1) In the October issue of European Heart Journal – Cardiovascular Pharmacotherapy, Dr Dellborg and co-workers report the efficacy and safety in the subpopulation recommended for treatment in ...
The findings were clear, but unexpected. “Since plaque erosion or rupture, thromboembolism, spontaneous coronary dissection and microvascular disorders are commonly encountered in MINOCA ...
Among various changes, the most remarkable is the new definition of target blood pressure in patients below 65 years of age on antihypertensive drugs as 120129 and <80 mmHg, while in the elderly, the ...
European Heart Journal, Lüscher, Thomas F
Dr. Esquirol said, “When we analysed the data using a Kaplan-Meier survival curve, we found a significantly higher cumulative incidence of death over time in the individuals given a wrinkle ...
The identification of peripheral artery disease (PAD) can help prevent further progression of the disease and additional complications, considering that this condition is a risk factor for all-cause ...
Data accumulated over the last 10 years strongly suggests that the risk of HF increases with the severity of abnormality of blood glucose, with an approximately linear relation between metabolic ...
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials Conclusion Beta-blockers improve LVEF ...
European Heart Journal, Cleland, John G F, Bunting, Karina V, Flather, Marcus D, Altman, Douglas G, Holmes, Jane, Coats, Andrew J S, Manzano, Luis, McMurray, John J V, Ruschitzka, Frank, van ...
[...]statin-treated post-myocardial infarction patients with residual inflammatory risk [defined by a persistently elevated high-sensitivity C-reactive protein (hsCRP)] have higher rates of recurrent ...
European Heart Journal, Ridker, Paul M
Aims We hypothesized that tissue inhibitor metalloproteinase-1 and matrix metalloproteinase-9 (TIMP-1 and MMP-9), biomarkers of fibrosis, would predict all-cause mortality and we assessed the ...
European Heart Journal, LaRocca, Gina, Aspelund, Thor, Greve, Anders M, Eiriksdottir, Gudny, Acharya, Tushar, Thorgeirsson, Gudmundur, Harris, Tamara B, Launer, Lenore J, Gudnason, Vilmundur, Arai, ...
Serelaxin has failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late breaking results presented for the first time today at Heart Failure 2017 and the 4th World ...